These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20195744)

  • 1. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
    Paridaens RJ; Gelber S; Cole BF; Gelber RD; Thürlimann B; Price KN; Holmberg SB; Crivellari D; Coates AS; Goldhirsch A
    Breast Cancer Res Treat; 2010 Aug; 123(1):303-10. PubMed ID: 20195744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
    O'Regan RM; Zhang Y; Fleming GF; Francis PA; Kammler R; Viale G; Dell'Orto P; Lang I; Bellet M; Bonnefoi HR; Tondini C; Villa F; Bernardo A; Ciruelos EM; Neven P; Karlsson P; Müller B; Jochum W; Zaman K; Martino S; Geyer CE; Jerzak KJ; Davidson NE; Coleman RE; Ingle JN; van Mackelenbergh MT; Loi S; Colleoni M; Schnabel CA; Treuner K; Regan MM
    JAMA Oncol; 2024 Oct; 10(10):1379-1389. PubMed ID: 39145953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
    Thürlimann B; Price KN; Gelber RD; Holmberg SB; Crivellari D; Colleoni M; Collins J; Forbes JF; Castiglione-Gertsch M; Coates AS; Goldhirsch A;
    Breast Cancer Res Treat; 2009 Jan; 113(1):137-44. PubMed ID: 18259856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
    Castiglione-Gertsch M; Johnsen C; Goldhirsch A; Gelber RD; Rudenstam CM; Collins J; Lindtner J; Hacking A; Cortes-Funes H; Forbes J
    Ann Oncol; 1994 Oct; 5(8):717-24. PubMed ID: 7826904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.
    Kim HA; Ahn SH; Nam SJ; Park S; Ro J; Im SA; Jung YS; Yoon JH; Hur MH; Choi YJ; Lee SJ; Jeong J; Cho SH; Kim SY; Lee MH; Kim LS; Moon BI; Kim TH; Park C; Kim SJ; Jung SH; Park H; Gwak GH; Kang SH; Kim JG; Kim J; Choi SY; Lim CW; Kim D; Yoo Y; Song YJ; Kang YJ; Jung SS; Shin HJ; Lee KJ; Han SH; Lee ES; Han W; Kim HJ; Noh WC
    BMC Cancer; 2016 May; 16():319. PubMed ID: 27197523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    Kalinsky K; Barlow WE; Gralow JR; Meric-Bernstam F; Albain KS; Hayes DF; Lin NU; Perez EA; Goldstein LJ; Chia SKL; Dhesy-Thind S; Rastogi P; Alba E; Delaloge S; Martin M; Kelly CM; Ruiz-Borrego M; Gil-Gil M; Arce-Salinas CH; Brain EGC; Lee ES; Pierga JY; Bermejo B; Ramos-Vazquez M; Jung KH; Ferrero JM; Schott AF; Shak S; Sharma P; Lew DL; Miao J; Tripathy D; Pusztai L; Hortobagyi GN
    N Engl J Med; 2021 Dec; 385(25):2336-2347. PubMed ID: 34914339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
    Hubalek M; Brantner C; Marth C
    Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant ovarian suppression in premenopausal breast cancer.
    Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; ;
    N Engl J Med; 2015 Jan; 372(5):436-46. PubMed ID: 25495490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
    Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
    J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant endocrine therapy for premenopausal women: Type and duration.
    Francis PA
    Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
    J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.